Drug Trial Radar · NCT06263244
Specifying the Anti-inflammatory Effects of Ziltivekimab
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
May 3, 2024
Primary completion
Oct 30, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.
Conditions
- Atherosclerosis
- Inflammation
Interventions
ZiltivekimabDrug
Monoclonal antibody targeting IL-6
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- TBRmax coronary arteriesTime frame: 5.5 months
- monocyte activation marker protein expressionTime frame: 5.5 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Amsterdam UMC, location AMC
Amsterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.